A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
At a glance
- Drugs PF 6291874 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 18 Mar 2014 Status changed to completed as reported by ClinicalTrials.gov.